The stock of Ovid Therapeutics Inc (NASDAQ: OVID) has increased by 1.43 when compared to last closing price of 0.3. Despite this, the company has experienced a 1.19% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-25 that Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs
Is It Worth Investing in Ovid Therapeutics Inc (NASDAQ: OVID) Right Now?
OVID has 36-month beta value of 0.08. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OVID is 59.51M, and currently, short sellers hold a 2.79% ratio of that float. The average trading volume of OVID on June 25, 2025 was 623.93K shares.
OVID’s Market Performance
The stock of Ovid Therapeutics Inc (OVID) has seen a 1.19% increase in the past week, with a 7.26% rise in the past month, and a -28.87% fall in the past quarter. The volatility ratio for the week is 5.46%, and the volatility levels for the past 30 days are at 4.75% for OVID. The simple moving average for the past 20 days is 1.47% for OVID’s stock, with a -57.89% simple moving average for the past 200 days.
Analysts’ Opinion of OVID
B. Riley Securities, on the other hand, stated in their research note that they expect to see OVID reach a price target of $9. The rating they have provided for OVID stocks is “Buy” according to the report published on April 30th, 2024.
H.C. Wainwright gave a rating of “Buy” to OVID, setting the target price at $9 in the report published on April 29th of the previous year.
OVID Trading at 1.27% from the 50-Day Moving Average
After a stumble in the market that brought OVID to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.18% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OVID starting from ALEXANDER MARGARET A., who sale 5,279 shares at the price of $0.56 back on Feb 26 ’25. After this action, ALEXANDER MARGARET A. now owns 73,406 shares of Ovid Therapeutics Inc, valued at $2,956 using the latest closing price.
Rona Jeffrey A, the CBFO of Ovid Therapeutics Inc, sale 3,902 shares at $0.56 during a trade that took place back on Feb 26 ’25, which means that Rona Jeffrey A is holding 67,973 shares at $2,185 based on the most recent closing price.
Stock Fundamentals for OVID
Current profitability levels for the company are sitting at:
- -104.04 for the present operating margin
- 0.73 for the gross margin
The net margin for Ovid Therapeutics Inc stands at -45.57. The total capital return value is set at -0.79. Equity return is now at value -36.31, with -23.42 for asset returns.
Based on Ovid Therapeutics Inc (OVID), the company’s capital structure generated 0.2 points at debt to capital in total, while cash flow to debt ratio is standing at -3.43.
Currently, EBITDA for the company is -61.27 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 27.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.93.
Conclusion
To put it simply, Ovid Therapeutics Inc (OVID) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
